ClinicaliQ Trial Snapshot
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. — Active Not Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06588686.
- Buloxibutid tested against placebo over 52 weeks in IPF patients to assess whether it slows lung function decline and is safe to use.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com Conditions: Idiopathic Pulmonary Fibrosis (IPF) Interventions: Buloxibutid, Placebo Lead Sponsor: Vicore Pharma AB Planned Enrollment: 378 participants